These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2874226)

  • 1. Buspirone analogues. 2. Structure-activity relationships of aromatic imide derivatives.
    New JS; Yevich JP; Eison MS; Taylor DP; Eison AS; Riblet LA; VanderMaelen CP; Temple DL
    J Med Chem; 1986 Aug; 29(8):1476-82. PubMed ID: 2874226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives.
    Yevich JP; Temple DL; New JS; Taylor DP; Riblet LA
    J Med Chem; 1983 Feb; 26(2):194-203. PubMed ID: 6131130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*,2S*,3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3- bicyclo[2.2.1]heptanedicarboximide (tandospirone) and related compounds.
    Ishizumi K; Kojima A; Antoku F
    Chem Pharm Bull (Tokyo); 1991 Sep; 39(9):2288-300. PubMed ID: 1687114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug.
    McMillen BA; Mattiace LA
    J Neural Transm; 1983; 57(4):255-65. PubMed ID: 6140299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
    Kääriäinen TM; Lehtonen M; Forsberg MM; Savolainen J; Käenmäki M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):50-8. PubMed ID: 17971064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat.
    McMillen BA; McDonald CC
    Neuropharmacology; 1983 Mar; 22(3):273-8. PubMed ID: 6133232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacology of buspirone hydrochloride.
    Skolnick P; Paul SM; Weissman BA
    Pharmacotherapy; 1984; 4(6):308-14. PubMed ID: 6151169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate.
    Shimizu H; Hirose A; Tatsuno T; Nakamura M; Katsube J
    Jpn J Pharmacol; 1987 Dec; 45(4):493-500. PubMed ID: 2895201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone.
    Protais P; Lesourd M; Comoy E
    Eur J Pharmacol; 1998 Jul; 352(2-3):179-87. PubMed ID: 9716353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover.
    Meltzer HY; Simonovic M; Fang VS; Gudelsky GA
    Psychopharmacology (Berl); 1982; 78(1):49-53. PubMed ID: 6128756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of carbamazepine and ipsapirone on turnovers of monoamines in the rat brain.
    Nibuya M; Kanba S; Kinoshita N; Suzuki E; Yagi G; Nakaki T; Kato R
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):127-8. PubMed ID: 1721659
    [No Abstract]   [Full Text] [Related]  

  • 12. Buspirone, ipsapirone and 1-(2-pyrimidinyl)-piperazine decrease cold-induced thyrotropin secretion in rats.
    Broqua P; Baudrie V; Bluet-Pajot MT; Chaouloff F
    Eur J Pharmacol; 1991 Nov; 204(2):141-7. PubMed ID: 1687218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover.
    Ballarín M; Carceller A; Guitart X
    Br J Pharmacol; 1994 Oct; 113(2):425-30. PubMed ID: 7530571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission.
    McMillen BA; Scott SM; Williams HL; Sanghera MK
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Apr; 335(4):454-64. PubMed ID: 2439924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine.
    Berlin I; Chalon S; Payan C; Schöllnhammer G; Cesselin F; Varoquaux O; Puech AJ
    Br J Clin Pharmacol; 1995 Mar; 39(3):243-9. PubMed ID: 7619663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic effects of buspirone, a novel anxiolytic agent.
    Cimino M; Ponzio F; Achilli G; Vantini G; Perego C; Algeri S; Garattini S
    Biochem Pharmacol; 1983 Mar; 32(6):1069-74. PubMed ID: 6838654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine receptor antagonism by the novel antianxiety drug, buspirone.
    McMillen BA; Matthews RT; Sanghera MK; Shepard PD; German DC
    J Neurosci; 1983 Apr; 3(4):733-8. PubMed ID: 6131948
    [No Abstract]   [Full Text] [Related]  

  • 18. Notes on buspirone's mechanisms of action.
    Garattini S; Caccia S; Mennini T
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):19-24. PubMed ID: 6130069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buspirone: chemical profile of a new class of anxioselective agents.
    Temple DL; Yevich JP; New JS
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):4-10. PubMed ID: 6185470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the effects of buspirone, BMY 13805, and 1-PP on dopaminergic metabolism in the nucleus accumbens using in vivo voltammetry in freely moving rats.
    Louilot A; Le Moal M; Simon H
    Life Sci; 1986 Aug; 39(8):685-92. PubMed ID: 2874469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.